Differences in circulating MMP-9 levels with regard to viral load and AST:ALT ratio between chronic hepatitis B and C patients

British Journal of Biomedical Science

Volumn 68, Issue 1, 2011, Pages 38-42

  Helaly, Ghada Fahmy ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Alanine transaminase; Aspartate aminotransferases; Hepatitis B; Hepatitis C; Matrix metalloproteinase 9

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GELATINASE B;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER DYSFUNCTION; LIVER INJURY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; VIRUS LOAD;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 80054840391     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2011.11732840     Document Type: Article

References (34)

1. Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol 2008; 22: 991-1008.
2. Jacobson IM. Therapeutic options for chronic hepatitis B: considerations and controversies. Am J Gastroenterol 2006; 101: S13-S18. (Pubitemid 43381696)
3. Wong SN, Lok AS. Update on viral hepatitis: 2005. Curr Opin Gastroenterol 2006; 22: 241-7. (Pubitemid 44090060)
4. Boonstra A, Woltman AM, Janssen HL. Immunology of hepatitis B and hepatitis C virus infections. Best Pract Res Clin Gastroenterol 2008; 22: 1049-61.
5. Parola M, Pinzani M. Hepatic wound repair. Fibrogenesis Tissue Repair 2009; 2: 4.
6. Povero D, Busletta C, Novo E et al. Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol 2010; 25: 1075-91.
7. Burt AD. Pathobiology of hepatic stellate cells. J Gastroenterol 1999; 34: 299-304. (Pubitemid 29332842)
8. Li D, Friedman SL. Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. 7 Gastroenterol Hepatol 1999; 14: 618-33. (Pubitemid 29350115)
9. Lichtinghagen R, Bahr M J, Wehmeier M et al. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin Sci 2003; 105: 373-82. (Pubitemid 37088577)
10. Giannelli G, Bergamini C, Marinosci F et al. Antifibrogenic effect of IFN-α2b on hepatic stellate cell activation by human hepatocytes. J Interferon Cytokine Res 2006; 26: 301-8. (Pubitemid 43801013)
11. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145-54.
12. Ljumovic D, Diamantis I, Alegakis AK, Kouroumalis EA. Differential expression of matrix metalloproteinases in viral and non-viral chronic liver diseases. Clin Chim Acta 2004; 349: 203-11. (Pubitemid 39312007)
13. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4. (Pubitemid 129519680)
14. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002; 3: 207-14.
15. Milani S, Herbst H, Schuppan D et al. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol 1994; 144: 528-37. (Pubitemid 24176758)
16. Lichtinghagen R, Huege O, Seifert T et al. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem 2000; 46: 2183-92.
17. Kwon OS, Lim DY, Kwon KA et al. Clinical usefulness of plasma activities of gelatinase (matrix metalloproteinase-2 and 9) in chronic liver disease (in Korean). Taehan Kan Hakhoe Chi 2003; 9: 222-30.
18. Giannini E, Risso D, Testa R. Transportability and reproducibility of the AST/ALT ratio in chronic hepatitis C patients. Am J Gastroenterol 2001; 96: 918-9. (Pubitemid 32240761)
19. Giannini E, Risso D, Botta F et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163: 218-24. (Pubitemid 36120190)
20. Mangoud AM, Sanad SM, Hendawy A, el-Hady G, el-Sherbiny GT Non-histological assessment of liver fibrosis in HCV infection. J Egypt Soc Parasitol 2004; 34: 383-95.
21. Ghany MG, Kleiner DE, Alter H et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104. (Pubitemid 36055343)
22. Prati D, Taioli E, Zanella A et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
23. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957; 28: 56-63.
24. Reif S, Somech R, Brazovski E et al. Matrix metalloproteinases 2 and 9 are markers of inflammation but not of the degree of fibrosis in chronic hepatitis C. Digestion 2005; 71: 124-30. (Pubitemid 40674580)
25. Kim JR, Kim CH. Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells. Int J Biochem Cell Biol 2004; 36: 2293-306. (Pubitemid 39094450)
26. Chung TW, Kim JR, Suh JI et al. Correlation between plasma levels of matrix metalloproteinase (MMP)-9/MMP-2 ratio and alpha-fetoproteins in chronic hepatitis carrying hepatitis B virus. J Gastroenterol Hepatol 2004; 19: 565-71.
27. Marinosci F, Bergamini C, Fransvea E et al. Clinical role of serum and tissue matrix metalloprotease-9 expression in chronic HCV patients treated with pegylated IFN-alpha2b and ribavirin. J Interferon Cytokine Res 2005; 25: 453-8. (Pubitemid 41193120)
28. Chung TW, Moon SK, Lee YC, Kim JG, Ko JH, Kim CH. Enhanced expression of matrix metalloproteinase-9 by hepatitis B virus infection in liver cells. Arch Biochem Biophys 2002; 408: 147-54. (Pubitemid 36027033)
29. Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J 2004; 18: 1123-5. (Pubitemid 39561544)
30. Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol 2001; 79: 515-36. (Pubitemid 33070441)
31. de Lalla C, Galli G, Aldrighetti L et al. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol 2004; 173: 1417-25. (Pubitemid 38924323)
32. Falasca K, Ucciferri C, Dalessandro M et al. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci 2006; 36: 144-50.
33. Núñez O, Fernández-Martínez A, Majano PL et al. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2 and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 2004; 53: 1665-72. (Pubitemid 39434113)
34. Sebastiani G. Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. World J Gastroenterol 2009; 15: 2190-203.